Search Results - "Richieri, S. P."

NeuroThera Efficacy and Safety Trial - 3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera Laser System for the treatment of acute ischemic stroke within 24h of stroke onset by Zivin, J A, Sehra, R, Shoshoo, A, Albers, G W, Bornstein, N M, Dahlof, B, Kasner, S E, Howard, G, Shuaib, A, Streeter, J, Richieri, S P, Hacke, W

“…Rationale Transcranial laser therapy is undergoing clinical trials in patients with acute ischemic stroke. The NeuroThera Efficacy and Safety Trial-1 was…”
Get full text

NeuroThera® Efficacy and Safety Trial – 3 (NEST-3): A Double-Blind, Randomized, Sham-Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Efficacy of Transcranial Laser Therapy with the NeuroThera® Laser System for the Treatment of Acute Ischemic Stroke within 24 h of Stroke Onset by Zivin, J. A., Sehra, R., Shoshoo, A., Albers, G. W., Bornstein, N. M., Dahlof, B., Kasner, S. E., Howard, G., Shuaib, A., Streeter, J., Richieri, S. P., Hacke, W.

“…Rationale Transcranial laser therapy is undergoing clinical trials in patients with acute ischemic stroke. The NeuroThera® Efficacy and Safety Trial-1 was…”
Get full text

Effect of Immunization with Inactivated gp120-Depleted Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen on HIV-1 Immunity, Viral DNA, and Percentage of CD4 Cells by Trauger, Richard J., Ferre, Francois, Daigle, Anne E., Jensen, Fred C., Moss, Ronald B., Mueller, Stewart H., Richieri, Steven P., Slade, Herbert B., Carlo, Dennis J.

“…A 1-year study measured the effect of administration of an inactivated human immunodeficiency virus type 1 (HIV-1) immunogen in incomplete Freund's adjuvant…”
Get full text

Phenotypic Analysis of Human Immunodeficiency Virus (HIV) Type 1 Cell-Mediated Immune Responses after Treatment with an HIV-1 Immunogen by Moss, Ronald B., Wallace, Mark R., Giermakowska, Wieslawa K., Webb, Erin, Savary, Jay, Chamberlin-Brandt, Carolyn, Theofan, Georgia, Musil, Roy, Richieri, Steven P., Jensen, Fred C., Carlo, Dennis J.

“…It was hypothesized that immune recognition could be stimulated with combined immune-based and potent antiviral drug therapies. This study examined human…”
Get full text

Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography by Richieri, Steven P., Bartholomew, Richard, Aloia, Roland C., Savary, Jay, Gore, Richard, Holt, John, Ferre, Francois, Musil, Roy, Tian, H.R., Trauger, Richard, Lowry, Peter, Jensen, Fred, Carlo, Dennis J., Maigetter, Robert Z., Prior, Christopher P.

“…This report characterizes inactivated, gp120 depleted, HIV-1 particles purified by an anion exchange chromatography production process. This antigen formulated…”
Get full text

A primer on HIV type 1-specific immune function and REMUNE by Moss, R B, Giermakowska, W K, Savary, J R, Theofan, G, Daigle, A E, Richieri, S P, Jensen, F C, Carlo, D J

“…The ability to recognize HIV antigens is lost early in HIV-1 infection. Individuals with nonprogressive HIV disease have been observed to mount strong immune…”
Get more information

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination by Lanza, Paola, Moss, Ronald B., Giermakowska, Wieslawa, Hancock, Richard B., Richieri, Steven P., Theofa, Georgia, Jensen, Fred C., Salk, Peter L., Carlo, Dennis J.

“…In this study, the effects were examined of dose and adjuvant of a whole-killed gp120-depleted HIV-1 antigen on antibody and cytokine responses in a murine…”
Get full text

Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy by MOSS, R. B, FERRE, F, SALK, J, LEVINE, A, TURNER, J, JENSEN, F. C, DAIGLE, A. E, RICHIERI, S. P, TRUCKENBROD, A, TRAUGER, R. J, CARLO, D. J

“…Two trials of subjects inoculated with the inactivated, gp120-depleted HIV-1 Immunogen are reported. In one study, in which 19 subjects received ZDV and 8…”
Get full text

Development and validation of a polymerase chain reaction method for the precise quantitation of HIV-1 DNA in blood cells from subjects undergoing a 1-year immunotherapeutic treatment by Ferre, F, Marchese, A L, Griffin, S L, Daigle, A E, Richieri, S P, Jensen, F C, Carlo, D J

“…To validate a quantitative polymerase chain reaction method developed to measure HIV-1 DNA in peripheral blood mononuclear cells. The assay was used to measure…”
Get more information

Inactivated HIV-1 Immunogen: impact on markers of disease progression by Moss, R B, Ferré, F, Trauger, R, Jensen, F, Daigle, A, Richieri, S P, Carlo, D J

“…The pursuit of valid markers of disease progression in human immunodeficiency virus type 1 (HIV-1) infection is especially relevant considering the potential…”
Get more information

Transcranial Laser Therapy in Acute Stroke Treatment: Results of Neurothera Effectiveness and Safety Trial 3, a Phase III Clinical End Point Device Trial by HACKE, Werner, SCHELLINGER, Peter D, ZIVIN, Justin, LEES, Kennedy R, ALBERS, Gregory W, BORNSTEIN, Natan M, DAHLOF, Bjorn L, FULTON, Rachael, KASNER, Scott E, SHUAIB, Ashfaq, RICHIERI, Steven P, DILLY, Stephen G

“…On the basis of phase II trials, we considered that transcranial laser therapy could have neuroprotective effects in patients with acute ischemic stroke. We…”
Get full text

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. 2. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide by Gold, D P, Smith, R A, Golding, AB, Morgan, EE, Dafashy, T, Nelson, J, Smith, L, Diveley, J, Laxer, JA, Richieri, S P, Carlo, D J, Brostoff, S W, Wilson, D B

“…We report here the results of a phase I trial of a T-cell receptor (TCR) V beta 6 CDR2 region peptide vaccine in 10 patients with multiple sclerosis who showed…”
Get full text

Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers by Eldon, M A, Smith, R A, Leese, P T, Daigle, A E, Katz, D V, Richieri, S P

“…T Cell Modulatory Peptide (TCMP-80), L-lysine-L-serine, is a synthetic dipeptide structurally related to a selected amino acid sequence in human immunoglobulin…”
Get more information

V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study by Moreland, L W, Heck, Jr, L W, Koopman, W J, Saway, P A, Adamson, T C, Fronek, Z, O'Connor, R D, Morgan, E E, Diveley, J P, Richieri, S P, Carlo, D J, Brostoff, S W

“…To determine whether modulation of activated T cells occurs in patients with rheumatoid arthritis (RA) after immunization with T cell receptor (TCR) V beta 17…”
Get more information

Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen : Long-term follow-up by LEVINE, A. M, GROSHEN, S, PARKER, J. W, SALK, P. L, SALK, J, ALLEN, J, MUNSON, K. M, CARLO, D. J, DAIGLE, A. E, FERRE, F, JENSEN, F. C, RICHIERI, S., TRAUGER, R. J

“…In 1987, exploratory clinical studies were initiated to determine whether the development of AIDS in HIV-infected individuals might be delayed or prevented by…”
Get full text

In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune) by Moss, R B, Wallace, M R, Lanza, P, Giermakowska, W, Jensen, F C, Theofan, G, Chamberlin, C, Richieri, S P, Carlo, D J

“…We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on…”
Get full text

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection by MOSS, R. B, TRAUGER, R. J, THEOFAN, G, CARLO, D. J, GIERMAKOWSKA, W. K, TURNER, J. L, WALLACE, M. R, JENSEN, F. C, RICHIERI, S. P, FERRE, F, DAIGLE, A. E, DUFFY, C

“…To measure beta-chemokine and cytokine production in HIV-1-infected subjects undergoing treatment with HIV-1 immunogen (REMUNE). Open label treatment study…”
Get full text

Viral load in peripheral blood mononuclear cells as surrogate for clinical progression by Ferre, F, Moss, R B, Daigle, A, Richieri, S P, Jensen, F, Carlo, D J

“…During the symposium on surrogate markers of HIV, the Scientific Advisory Committee posed the following question: "Which surrogate markers currently deserve…”
Get more information

NeuroThera registered Efficacy and Safety Trial - 3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera registered Laser System for the treatment of acute ischemic stroke within 24 h of stroke onset by Zivin, JA, Sehra, R, Shoshoo, A, Albers, G W, Bornstein, N M, Dahlof, B, Kasner, SE, Howard, G, Shuaib, A, Streeter, J, Richieri, S P, Hacke, W

“…Transcranial laser therapy is undergoing clinical trials in patients with acute ischemic stroke. The NeuroThera registered Efficacy and Safety Trial-1 was…”
Get full text

Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects by Moss, R B, Giermakowska, W, Lanza, P, Turner, J L, Wallace, M R, Jensen, F C, Theofan, G, Richieri, S P, Carlo, D J

“…Lymphocyte proliferation responses to gp120-depleted HZ321 virus (clade A) antigen were compared to BAL human immunodeficiency virus (HIV) virus antigen (clade…”
Get more information